title: Combination of Bevacizumab and NGF Reduces the Risk of Diabetic Retinopathy.
abstract: Accumulated evidences support diabetic retinopathy is caused by functional and structural alterations in both the microvascular and neuroglial compartments. Here, we explored any beneficial effects of combination of Bevacizumab and NGF to prevent diabetic retinopathy. STZ-induced diabetic rats were randomly grouped into three groups: sham, Bevacizumab and combination group (Bevacizumab + NGF). End of the treatment, vascular abnormality was evaluated by FITC-dextran. Inflammation and angiogenesis factors were also investigated by real-time PCR and western blot. Our results showed both Bevacizumab and the combination could dramatically reduce abnormal vascular permeability and limit the inflammatory and angiogenesis in 6-week diabetic rats. However, the combination indicated better preventive effects in 12-week diabetic rats compared with Bevacizumab alone. Our findings suggest that the combination of Bevacizumab with NGF may be a new method for the preventive intervention of diabetic retinopathy.
authors: Department of Ophthalmology, The Affiliated Hospital of Binzhou Medical College, Binzhou, Shandong, People's Republic of China.
authors: Peipei
authors: P
authors: Zhang
authors: Qingdao Municipal Hospital, No.1 Jiaozhou Road, Qingdao, Shandong, People's Republic of China. zhouzhanyu1125@163.com.
authors: Zhanyu
authors: Z
authors: Zhou
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000068258:Bevacizumab / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002199:Capillary Permeability; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000517:prevention & control*; D004338:Drug Combinations; D004357:Drug Synergism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005260:Female; D020932:Nerve Growth Factor / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D020533:Angiogenesis Inhibitors; D004338:Drug Combinations; D000068258:Bevacizumab; D020932:Nerve Growth Factor
keywords: Angiogenesis; Bevacizumab; Diabetic retinopathy; Inflammation; NGF